KWF

Implementation of Biomarkers

€1M–€4M| Deadline: 20 October 2026 (107 days)|3-5 years

Pre-proposal deadline 12:00 noon; full proposal deadline 23 February 2027 (12:00 noon)

Last verified: 5 July 2026

Is this grant right for you? Check your personalised match score. 30s, no email. See my matches →

Details

Funder	KWF
Budget	€1M–€4M
Deadline	20 October 2026
Duration	3-5 years
Consortium	Required — minimum 4 participating parties (may include private partners)
Application	2-stage: pre-proposal (opens 25 Aug 2026, closes 20 Oct 2026) → full proposal (opens 15 Dec 2026, closes 23 Feb 2027) → interviews May 2027 → funding decision June 2027
TRL	7-9
Frequency	Annual
Eligible countries	NL

Eligibility & scope

Open to multidisciplinary consortia (min. 4 parties) aiming to implement a clinically validated biomarker (TRL 7–9) into nationwide routine oncology care in the Netherlands. Mandatory components include an HTA specialist in the team, a KWF-approved steering committee, and a patient perspective embedded throughout. Public-private collaborations encouraged with co-funding. PhD candidates strongly discouraged. Proposals must be submitted via KWF GMS.